Fig. 2

A The Spearman’s correlation coefficient reveals a negative association between aneuploidy score and immune signature. B Spearman's correlation of PDL1 with aneuploidy scores in TCGA HNSCC patients. C Spearman's correlation of the 22-gene MYC signature (Ganci et al.). D Distributions of the aneuploidy scores between TP53 mutated patients, WT patients and co-mutated patients. Co-mutated patients show lower aneuploidy than TP53 mutated patients. Statistical significance was evaluated by Wilcoxon test. E Forest plot and multivariate regression model to assess the weights in the immune gene sets prediction of the aneuploidy score and the TP53 co-mutational status. The variables resulted to be independent predictors of the immune signature. F Cell types enrichment analysis by comparing 64 cell type signatures in subgroups of HNSCC patients with TP53 mutation, TP53 mutation with other mutations and wild type patients. Heatmap representing the normalized average scores obtained from Xcell software, reflecting the cell type abundance of the most significant modulated cell types among the three subgroups. The statistical significance (p < 0.05) was assessed by KruskalWallis test. G Overall survival (left panel) and Progression free survival (right panel) of 102 patients treated with PDL1 inhibitors from GEO database (GSE159067). Patients were split basing on the Immune Score. The high\low levels of Immune Score were obtained considering the positive and negative z-scores of the average expression of the 26 immune gene sets, respectively. Differences between curves were evaluated by logrank test. The multivariate Cox Hazard regression analysis was adjusted for gender and HPV status. H Average expression of the 26 immune gene sets and MYC signature distribution in 102 patients treated with PDL1 inhibitors (GSE159067, left and right panel, respectively). The immune gene sets expression was evaluated in patients with complete or partial response and patients with stable disease or progression disease after treatment (Fig. 2H, left panel). The MYC signature expression was evaluated according to the phenotype classification (“COLD” and “HOT” patients) obtained from Foy JP and colleagues (Fig. 2H, right panel). Differences were evaluated by Wilcoxon test. I The overall survival of 139 HNSCC patients in Samstein's cohort (MSKCC) who underwent ICI treatment was analyzed based on their mutational status. P-values were assessed using the logrank test